Mr. Ken d'Entremont reports

MEDEXUS SCHEDULES FIRST FISCAL QUARTER 2024 CONFERENCE CALL

Medexus Pharmaceuticals Inc. will hold a conference call at 8 a.m. ET on Thursday, Aug. 10, 2023, to discuss Medexus's results for its first fiscal quarter ended June 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on August 9, 2023.

To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011 for international callersAccess code: 550553

A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:https://www.webcaster4.com/Webcast/Page/2010/48802

A replay of the call will be available approximately one hour following the end of the call through Thursday, August 17, 2023. To access the replay, please dial the following numbers -877-481-4010 for Canadian and U.S. callers+1 919-882-2331 for international callersConference ID: 48802

A replay of the webcast will be available on the Investors section of Medexus's corporate website until Saturday, August 10, 2024.

About Medexus

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.

We seek Safe Harbor.